Literature DB >> 3729125

Inhibition of African swine fever infection in the presence of immune sera in vivo and in vitro.

F Ruiz Gonzalvo, M E Carnero, C Caballero, J Martínez.   

Abstract

In assay cultures, sera from African swine fever convalescent pigs inhibited infection by homologous African swine fever virus. The infection-inhibition capacity did not correspond with the virus-neutralizing capacity. The serum did not prevent infection by heterologous virulent viruses. Sera from pigs challenge inoculated with the homologous virulent virus and later with a heterologous virulent virus inhibited the infection by different heterologous virulent viruses. These sera did not interfere with the infection by pseudorabies virus. The specificity of the reaction indicated that the infection inhibition was caused by antibody.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729125

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  22 in total

1.  Neutralizing antibodies to different proteins of African swine fever virus inhibit both virus attachment and internalization.

Authors:  P Gómez-Puertas; F Rodríguez; J M Oviedo; F Ramiro-Ibáñez; F Ruiz-Gonzalvo; C Alonso; J M Escribano
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

2.  Detection of African swine fever virus antibodies by immunoblotting assay.

Authors:  M J Pastor; M D Laviada; J M Sanchez-Vizcaino; J M Escribano
Journal:  Can J Vet Res       Date:  1989-01       Impact factor: 1.310

3.  Simultaneous Deletion of the 9GL and UK Genes from the African Swine Fever Virus Georgia 2007 Isolate Offers Increased Safety and Protection against Homologous Challenge.

Authors:  Vivian O'Donnell; Guillermo R Risatti; Lauren G Holinka; Peter W Krug; Jolene Carlson; Lauro Velazquez-Salinas; Paul A Azzinaro; Douglas P Gladue; Manuel V Borca
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

4.  Inhibition of IL-2R and SLA class II expression on stimulated lymphocytes by a suppressor activity found in homogenates of African swine fever virus infected cultures.

Authors:  A Canals; J Domínquez; J Tomillo; M Babín; F Alonso
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Induction of Robust Immune Responses in Swine by Using a Cocktail of Adenovirus-Vectored African Swine Fever Virus Antigens.

Authors:  Shehnaz Lokhandwala; Suryakant D Waghela; Jocelyn Bray; Cameron L Martin; Neha Sangewar; Chloe Charendoff; Rashmi Shetti; Clay Ashley; Chang-Hsin Chen; Luc R Berghman; Duncan Mwangi; Paul J Dominowski; Dennis L Foss; Sharath Rai; Shaunak Vora; Lindsay Gabbert; Thomas G Burrage; David Brake; John Neilan; Waithaka Mwangi
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

6.  African swine fever virus infection induces tumor necrosis factor alpha production: implications in pathogenesis.

Authors:  M Gómez del Moral; E Ortuño; P Fernández-Zapatero; F Alonso; C Alonso; A Ezquerra; J Domínguez
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Recombinant antigen targets for serodiagnosis of African swine fever.

Authors:  Carmina Gallardo; Ana Luísa Reis; Gladys Kalema-Zikusoka; Joana Malta; Alejandro Soler; Esther Blanco; R M E Parkhouse; Alexandre Leitão
Journal:  Clin Vaccine Immunol       Date:  2009-05-06

8.  African Swine Fever Virus MGF-110-9L-deficient Mutant Has Attenuated Virulence in Pigs.

Authors:  Dan Li; Yinguang Liu; Xiaolan Qi; Yuan Wen; Pan Li; Zhao Ma; Yongjie Liu; Haixue Zheng; Zhijie Liu
Journal:  Virol Sin       Date:  2021-03-10       Impact factor: 4.327

9.  Thoughts on African Swine Fever Vaccines.

Authors:  Daniel L Rock
Journal:  Viruses       Date:  2021-05-20       Impact factor: 5.048

10.  DNA vaccination partially protects against African swine fever virus lethal challenge in the absence of antibodies.

Authors:  Jordi M Argilaguet; Eva Pérez-Martín; Miquel Nofrarías; Carmina Gallardo; Francesc Accensi; Anna Lacasta; Mercedes Mora; Maria Ballester; Ivan Galindo-Cardiel; Sergio López-Soria; José M Escribano; Pedro A Reche; Fernando Rodríguez
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.